News: big pharma is not happy about this newly public information

Saturday, August 19, 2023

big pharma is not happy about this newly public information

If for any reason you believe you received this email in error click here to unsubscribe.

It is a priority at iDigitalMarket to identify and bring to the attention of our valued readers, opportunities of significance. Please take the time to review the message below from our colleagues that we believe will be of interest to you.

By now, you have heard the news rumblings.

After 10 years of testing, Conolidine "Nature's Morphine" is APPROVED to come to the US market effective immediately.

As you now know, Conolidine is the most powerful natural pain reliever in the world, boasting pharmaceutical level relief with no negative effects.

Remember this Harvard headline?

This is just one of MANY now online.

click here!

>>> Go here to learn how Conolidine eases daily pain without side effects or addiction risk

Imagine a relief compound 20X the power of CBD.

Imagine lowering your pain levels by 80% or 90% without any drugs or life changes.

…. And at 1/10th the cost of dangerous "pain management"

As of today you can access all of this without a script or even a doctor's visit.

>>> All you have to do is visit this page to access the first Conoldine formula publicly available

If you hurt daily you could be minutes away from a lifetime of relief.

To confirm, Conolidine is certified drug-free and legal to use in the US and all over the world.

You can even travel with it.

>>> All you have to do is visit this exclusive page dedicated to Conolidine

Clint Winters, Medical Scientist

P.S. One last bit of info, this powerful ingredient has gone through five years of clinical testing showing a 92% relief success rate.

>>> You can view the stunning results here

P.P.S. Final thought - Big Pharma is not happy about this newly public information, they could try to censor this page at any time.

iDigital Market
14422 Shoreside Way Suite 110-238 Winter Garden, FL 34787

About Us | Privacy Policy | Terms & Conditions

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)